New drug combo aims to slow advanced prostate cancer
Disease control
Not yet recruiting
This early-stage trial tests the safety of combining a radioactive drug (lutetium DGUL) with an immunotherapy (pembrolizumab) in 30 men with metastatic castration-resistant prostate cancer that has stopped responding to standard hormone therapy. Participants receive the radioacti…
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:24 UTC